Celanese Announces Agreement with the Population Council for Sustained Release Dual-API Therapeutic
12 Septiembre 2023 - 8:30AM
Business Wire
Celanese VitalDose® Drug Delivery Platform Will
Enable the Population Council’s Contraceptive and HIV Multipurpose
Prevention Technology
Celanese Corporation (NYSE: CE), a global specialty materials
and chemical company, today announced that it has entered into an
agreement with the Population Council to supply its VitalDose® Drug
Delivery Platform for use in a new Multipurpose Prevention
Technology (MPT) Intravaginal Ring (IVR). The IVR is being
developed to provide both contraception and protection against HIV
and is currently in a phase 1b clinical trial.
Long-acting continuous drug delivery dose forms, like IVRs,
offer fewer barriers to reliable use than oral forms requiring
daily doses. Providing benefits for patients, like enhanced
convenience, can lead to better outcomes and is the driver for
developing patient-centric dose forms. The VitalDose Drug Delivery
Platform has been used in patient-centric dose forms in women’s
health for over two decades, offering tunable and consistent
elution for a variety of active pharmaceutical ingredient (API)
molecules.
“Our data indicate that women overwhelmingly prefer, and are
more likely to use, a multipurpose prevention product that prevents
pregnancy and sexually transmitted infection acquisition over a
product that prevents only one of the two,” said Bríd Devlin, Chief
Scientific Officer of Product Development at the Population
Council. “This IVR would address the need for a contraceptive
solution while also providing preventive therapy against HIV at a
time when 63 percent of new HIV infections are contracted by women
and girls.”
“There is an undeniable need for new patient-centric
technologies that provide women with new healthcare options and
address the overlapping global burdens of unintended pregnancy and
HIV,” said Susan Rahe, Vice President of Pharmaceutical Solutions
at Celanese. “Our team recognizes the benefits of a sustained
release dose form to further the work of Population Council as they
continue to develop global treatments to benefit the lives of
patients.”
The VitalDose Drug Delivery Platform provides reliable,
controlled-release performance for a wide range of molecule types
and has a long history of use in approved parenteral drug products
in the United States, Europe and many other geographies. For more
information on Celanese VitalDose technology, visit
www.vitaldose.com.
About Celanese
Celanese Corporation is a global chemical leader in the
production of differentiated chemistry solutions and specialty
materials used in most major industries and consumer applications.
Our businesses use the full breadth of Celanese's global chemistry,
technology and commercial expertise to create value for our
customers, employees, shareholders and the corporation. As we
partner with our customers to solve their most critical business
needs, we strive to make a positive impact on our communities and
the world through The Celanese Foundation. Based in Dallas,
Celanese employs approximately 13,000 employees worldwide and had
2022 net sales of $9.7 billion. For more information about Celanese
Corporation and its product offerings, visit www.celanese.com.
About the Population Council
The Population Council is a leading research organization
dedicated to building an equitable and sustainable world that
enhances the health and well-being of current and future
generations. We generate ideas, produce evidence, and design
solutions to improve the lives of underserved populations around
the world. Learn more at www.popcouncil.org.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230912694417/en/
Celanese Contacts:
Investor Relations Brandon Ayache Phone: +1 972 443 8509
brandon.ayache@celanese.com
Media Relations – Global Brian Bianco Phone: +1 972 443
4400 media@celanese.com
Media Relations Europe (Germany) Petra Czugler Phone: +49
69 45009 1206 petra.czugler@celanese.com
Population Council Contacts:
Media Inquiries pubinfo@popcouncil.org Visit our Media
section
Partnerships development@popcouncil.org
Product licensing opportunities Anita Garg
agarg@popcouncil.org
Celanese (NYSE:CE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Celanese (NYSE:CE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024